Lipid-based delivery is the most credible answer the industry has found to a brutal truth: most new drug molecules cannot dissolve well enough to work. Thirty years on, that answer has a visible ceiling — and the next move is not to optimise it, but to engineer past it.
The problem was never the molecule. It was the form we forced it into — and what that form makes the body do first.
Why medicine turned to lipids
Between 70 and 90 per cent of compounds in the development pipeline are poorly water-soluble, and a large share of marketed drugs are limited not by crossing the gut wall but by dissolving in the first place. Lipid-based systems became the workaround: carry a stubborn molecule in an oil or surfactant blend so it never has to dissolve in water unaided.
The ceiling of conventional lipid systems
The catch is that most lipid systems still depend on the body digesting and dispersing them before the drug is released. Performance becomes tied to digestion, food and timing — useful, but still paced by a step nobody fully controls. The honest next question is whether delivery can be organised so that it does not wait on dissolution or digestion at all.
Liquid crystals: order inside a fluid
There is a state of matter between solid and liquid — the liquid crystal — that flows like a fluid while keeping the ordered structure of a crystal. Certain lipids self-assemble into these ordered phases in contact with water. That order is not decoration: it changes how a material holds a drug and how it meets a biological surface. It is one of the most interesting, and least exploited, tools in formulation.
Where Ibumix works
Ibumix is developing a series of new liquid drug-delivery platforms built on glyceryl caprate (GCC) lipid chemistry, re-engineering how established medicines are delivered — beginning with the NSAID class. The approach deliberately uses well-characterised, GRAS-status materials rather than novel synthetic enhancers, a way to reduce regulatory and safety risk from the outset. The focus is small molecules, where the same dissolution-and-absorption arithmetic applies, and where the competitive reference point is the medium-chain enhancer field — such as C10 and SNAC — rather than nanotechnology.
The next chapter in oral delivery is being written by lipids — and by the order you can build into them.
Read deeper
- Beyond Dissolution: Reframing Lipid Functionality — why the dissolution-dependent system has reached its ceiling.
- Polysorbate Architecture — the surfactant chemistry behind solubilisation and emulsification.
- Engineering the Next Generation of Pharmaceutical Excipients — why the excipient, not only the drug, decides performance.
- Bioavailability: the medicine that never arrives — the absorption problem these systems exist to solve.
- Why the tablet is pharma’s bottleneck — the format that lipid delivery moves beyond.
About Ibumix
Ibumix is developing a series of new liquid drug-delivery platforms built on glyceryl caprate (GCC) lipid chemistry — re-engineering how established medicines are delivered, beginning with the NSAID class. Ibuprofen and naproxen are the starting points; the opportunity extends well beyond them.
Sources
- Poorly-soluble pipeline figure — Lipinski (2000); Di et al. (2012).
- Biopharmaceutics Classification System (BCS) — FDA BCS guidance.
- Lipid liquid-crystal mesophases in formulation — lipid-formulation literature.
- GRAS status — US FDA GRAS framework (status bounded by use and level).
See how this connects to what Ibumix is building: the Mix platform — one architecture, seven chassis.